

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ruben et al.

Docket No.: PZ029P1D3

Application No.: Not Yet Assigned

Confirmation No.:

Filed: Concurrently Herewith

Art Unit: N/A

For: 94 Human Secreted Proteins

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references AA-BO listed on the attached Form PTO/SB/08.

Copies of references AA, AF-AG, AP-BM, and BO were submitted by Applicants or cited by the Examiner in connection with U.S. Application No. 09/461,325, filed on December 14, 1999, and copies of references AB-AE, AH-AO, and BN were submitted by Applicants or cited by the Examiner in connection with U.S. Application No. 10/115,123, filed April 4, 2002, to both of which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of U.S. Application No. 09/461,325 and U.S. Application No. 10/115,123 for copies of references AA-BO.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such

references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: March 16, 2004

Respectfully submitted,

By 
Janet M. Martineau

Registration No.: 46,903
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(301) 315-2723

JMM/KC/lcc/ba

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>											
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<table border="1"> <tr> <td>Application Number</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Filing Date</td> <td>Concurrently Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Ruben et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>N/A</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> </table>		Application Number	Not Yet Assigned	Filing Date	Concurrently Herewith	First Named Inventor	Ruben et al.	Group Art Unit	N/A	Examiner Name	Not Yet Assigned
Application Number	Not Yet Assigned														
Filing Date	Concurrently Herewith														
First Named Inventor	Ruben et al.														
Group Art Unit	N/A														
Examiner Name	Not Yet Assigned														
Sheet	1	of	3	Attorney Docket Number	PZ029P1D3										

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	AA	5,534,409		Groner et al.	07/09/1996
	AB	5,250,414		Schwab et al.	10/05/1993
	AC	5,684,133		Schwab et al.	11/04/1997
	AD	6,103,232		Schwab et al.	08/15/2000
	AE	5,011,912		Hopp et al.	04/30/1991

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴ (if known)		
	AF	WO	99/66041	Human Genome Sciences, Inc.	12/23/1999
	AG	WO	01/51520	A2 Yale University	07/19/2001
	AH	WO	99/46281	A2 Genentech, Inc.	09/16/1999
	AI	WO	00/32221	A2 Genentech, Inc.	06/08/2000
	AJ	WO	00/37638	A2 Genentech, Inc.	06/29/2000
	AK	WO	00/53758	A2 Genentech, Inc.	09/14/2000
	AL	WO	00/53756	A2 Genentech, Inc.	09/14/2000
	AM	WO	00/70050	A1 Genentech, Inc.	11/23/2000
	AN	WO	00/73452	A2 Genentech, Inc.	12/07/2000
	AO	WO	01/40466	A2 Genentech, Inc.	06/07/2001

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Not Yet Assigned
Sheet	2	of	3	Filing Date	Concurrently Herewith
				First Named Inventor	Ruben et al.
				Group Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	PZ029P1D3

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AP	Geneseq Accession No. AAY86244, "Human secreted protein HCEJQ69, SEQ ID NO:159." (12/23/1999)			T ²
	AQ	Geneseq Accession No. AAY41745, "Human PRO526 protein sequence." (09/16/1999)			
	AR	Geneseq Accession No. AAB44301, "Human PRO526 (UNQ330) protein sequence SEQ ID NO:400." (09/14/2000)			
	AS	Geneseq Accession No. AAB33426, "Human PRO526 protein UNQ330 SEQ ID NO:62." (09/14/2000)			
	AT	Geneseq Accession No. AAB24410, "Human PRO526 protein sequence SEQ ID NO:127." (06/08/2000)			
	AU	Geneseq Accession No. AAY95345, "Human PRO526 antitumour protein." (06/29/2000)			
	AV	Geneseq Accession No. AAB50908, "Human PRO526 protein." (12/07/2000)			
	AW	Geneseq Accession No. AAB49891, "Human PRO526 protein sequence." (11/23/2000)			
	AX	Genbank Accession No. AAG53612, "Nogo receptor [Homo sapiens]." (01/24/2001)			
	AY	Genbank Accession No. AAG53611, "Nogo receptor [Mus musculus]." (01/24/2001)			
	AZ	Genbank Accession No. AX047642, "Sequence 1 from Patent WO0070050." (12/15/2000)			
	BA	Genbank Accession No. AA452195, "zx30d02.r1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:787971 5' similar to SW:ALS_HUMAN P35858 insulin-like growth factor binding protein complex acid labile chain precursor, mRNA sequence." (06/05/1997)			
	BB	Genbank Accession No. AA436362, "zv32e09.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755368 3', mRNA sequence." (05/30/1997)			
	BC	Genbank Accession No. H08678, "yl93d10.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:46062 3', mRNA sequence." (06/23/1995)			
	BD	Genbank Accession No. AA428418, "zw32d07.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:770989 5', mRNA sequence." (10/16/1997)			
	BE	Genbank Accession No. AA427404, "zw32d07.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:770989 3', mRNA sequence." (10/16/1997)			
	BF	Genbank Accession No. AA410412, "zv32g09.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755392 5', mRNA sequence." (05/18/1997)			
	BG	Genbank Accession No. AA410413, "zv32g09.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755392 3', mRNA sequence." (05/18/1997)			
	BH	Genbank Accession No. H08677, "yl93d10.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:46062 5' similar to SP:CBP8_HUMAN P22792 carboxypeptidase N 83 KD chain, mRNA sequence." (06/23/1995)			

Examiner Signature		Date Considered
--------------------	--	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					
Sheet	3	of	3	Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Ruben et al.
				Group Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	PZ029P1D3

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BI	FOURNIER ET AL., "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration", Nature, 409(6818):341-346 (2001)
	BJ	GRANDPRE et al., "Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein", Nature, 403(6768):439-444 (2000)
	BK	GOLDBERG ET AL., "Nogo in nerve regeneration", Nature, 403(6768):369-370 (2000)
	BL	JACOBS ET AL., "A genetic selection for isolating cDNAs encoding secreted proteins", Gene, 198:289-296 (1997)
	BM	BRITTIS, ET AL., "Nogo Domains and a Nogo Receptor: Implications for Axon Regeneration," Neuron 30:11-14 (2001).
	BN	Ng, C.E. and B.L. Tang., "Nogos and the Nogo-66 Receptor: Factors inhibiting CNS neuron regeneration," J. Neurosci Res 67(5):559-565 (2002).
	BO	GrandPrè, T., et al., "Nogo-66 Receptor Antagonist Peptide Promotes Axonal Regeneration," Nature Vol 417 (30 May 2002)

Examiner Signature		Date Considered
--------------------	--	-----------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.